| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 09/30/2009 | CN100544770C Method for detecting and killing epithelial cancer cells |
| 09/30/2009 | CN100544717C Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
| 09/30/2009 | CN100544714C Composition for solubilization of paclitaxel and preparation method thereof |
| 09/29/2009 | US7595429 Calcium zeolite hemostatic agent |
| 09/29/2009 | US7595347 Pretreatment with alpha, beta-unsaturated aryl sulfone as cytoprotectant; side effect reduction during cancer treatment; mitotic phase cell cycle inhibitor or topoisomerase inhibitors |
| 09/29/2009 | US7595299 Peptides as NS3-serine protease inhibitors of hepatitis C virus |
| 09/29/2009 | US7595067 Composition and method to augment and sustain neurotransmitter production |
| 09/29/2009 | US7595051 Methods of treating neovascular glaucoma, macular degeneration and capillary proliferation with alphavbeta3-specific antibodies |
| 09/29/2009 | US7595044 Artery-and vein-specific proteins and uses therefor |
| 09/29/2009 | US7595039 Methods of healing wounds by administering human IL-18 |
| 09/29/2009 | CA2469350C 3-{4-methyl-3[methyl-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile mono citrate salt |
| 09/29/2009 | CA2457944C Polycyclic guanine phosphodiesterase v inhibitors |
| 09/29/2009 | CA2390295C A method for chemoprevention of prostate cancer |
| 09/29/2009 | CA2310850C A covalent conjugate of clozapine with a fatty acid and its use for treating schizophrenia |
| 09/29/2009 | CA2289531C Composition and methods for treating alzheimer's disease and other amyloidoses |
| 09/29/2009 | CA2273852C Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases |
| 09/29/2009 | CA2240737C A long qt syndrome gene which encodes kvlqt1 and its association with mink |
| 09/24/2009 | WO2009117482A1 Mtor inhibitor salt forms |
| 09/24/2009 | WO2009116887A1 Pharmaceutical composition of antibiotics and prebiotics for preventing and treating dysbiosis during antibacterial therapy |
| 09/24/2009 | WO2009116886A1 Pharmaceutical composition for preventing dysbiosis associated with enteral administration of antibiotics |
| 09/24/2009 | WO2009115666A2 Combination of a bis-thiazolium salt or a precursor thereof and artemisinin or a derivative thereof for treating acute malaria |
| 09/24/2009 | WO2009115652A2 Composition and methods used during anti-hiv treatment |
| 09/24/2009 | WO2009115301A1 Solid pharmaceutical composition comprising a non-peptide angiotensin ii receptor antagonist and a diuretic |
| 09/24/2009 | WO2009091538A3 Pharmaceutical composition comprising epa and dha for treating hypertriglyceridemia and hypercholesterolemia |
| 09/24/2009 | WO2009074794A3 Anti-inflammatory compositions and combinations |
| 09/24/2009 | WO2009047291A3 Use of quaternary pyridinium salts for inhibiting cancer metastases |
| 09/24/2009 | WO2008144423A3 Compositions comprising a gpr109 ligand for treating disorders of the digestive tract and/or cancer |
| 09/24/2009 | WO2007116409A4 Improved vaccines comprising multimeric hsp60 peptide carriers |
| 09/24/2009 | US20090239916 Novel drug discovery target and medicine acting on the same |
| 09/24/2009 | US20090239878 Combinations of (a) an atp-competitive inhibitor of c-abl kinase activity with (b) two or more other antineoplastic agents |
| 09/24/2009 | US20090239844 Ace inhibitor-vasopressin antagonist combinations |
| 09/24/2009 | US20090239236 Gene detection assay for improving the likelihood of an effective response to an egfr antagonist cancer therapy |
| 09/24/2009 | US20090238907 Topical Compositions Containing Bacillus Coagulans Extracellular Products and Uses Thereof |
| 09/24/2009 | US20090238886 Retro-Inversion Peptides That Target GIT Transport Receptors and Related Methods |
| 09/24/2009 | US20090238874 Biomimetic composition reinforced by a polyelectrolytic complex of hyaluronic acid and chitosan |
| 09/24/2009 | US20090238832 Novel compositions and method for the treatment of psoriasis |
| 09/24/2009 | US20090238818 Induction of Antigen Specific Immunnologic Tolerance |
| 09/24/2009 | US20090238770 Organic compounds |
| 09/24/2009 | CA2716924A1 Mtor inhibitor salt forms |
| 09/24/2009 | CA2715350A1 Solid pharmaceutical composition comprising a non-peptide angiotensin ii receptor antagonist and a diuretic |
| 09/24/2009 | CA2714184A1 Combination of a bis-thiazolium salt or a precursor thereof and artemisinin or a derivative thereof for treating acute malaria |
| 09/24/2009 | CA2711569A1 Composition and methods used during anti-hiv treatment |
| 09/23/2009 | EP2103624A1 Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
| 09/23/2009 | EP2103312A1 Preparation for sterilization or disinfection of tissue |
| 09/23/2009 | EP2102331A1 Anti-tumor vaccine derived from normal chemically modified cells |
| 09/23/2009 | EP2101820A2 Combination of a retinoid and a platinum anticancer agent |
| 09/23/2009 | EP2101819A2 Methods, compositions, and kits for treating pain and pruritis |
| 09/23/2009 | EP2101805A2 Specific therapy and medicament using integrin ligands for treating cancer |
| 09/23/2009 | EP2101790A1 Combination comprising cndac (2'-cyano-2'-deoxy-n4-palmitoyl-1-beta-d-arabinofuranosyl-cytosine) and a cytotoxic agent |
| 09/23/2009 | EP2101780A2 Methods of treating chronic inflammatory diseases using a gm-csf antagonist |
| 09/23/2009 | EP2101763A2 Pharmaceutical compositions and their methods of use |
| 09/23/2009 | EP1799204B1 Composition containing omega-3 fatty acids and omega-6 fatty acids |
| 09/23/2009 | EP1768748B1 Compositions comprising strontium and vitamin d and uses thereof |
| 09/23/2009 | EP1651213B1 Use of angiotensin ii receptor antagonists, especially telmisartan, in order to increase insulin sensitivity |
| 09/23/2009 | EP1542528B1 A method of treatment and prophylaxis |
| 09/23/2009 | EP1435935B1 Concentrated x-ray contrast media can act as universal antigens and can inhibit or prevent allergic reactions |
| 09/23/2009 | EP1377288B1 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase iv and use |
| 09/23/2009 | EP1214944B1 Composition for PERCUTANEOUS ABSORPTION with a compound having a melatonin receptor agonist activity |
| 09/23/2009 | EP1003781B1 Interleukin-18 binding proteins, their preparation and use |
| 09/23/2009 | CN101538236A Method for synthesizing lauroyl-prolyl amino acid methyl ester as novel transdermal enhancer and applications thereof |
| 09/23/2009 | CN101537182A Combination comprising an HMG CoA reductase inhibitor and an insulin secretor enhancer or an insulin sensitizer |
| 09/23/2009 | CN101537181A Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and / or congestive heart failure |
| 09/23/2009 | CN100542612C Lipidated glycosaminoglycan particles and their use in drug and gene delivery for diagnosis and therapy |
| 09/23/2009 | CN100542608C Agent elevating dendritic cell precursor level in blood |
| 09/23/2009 | CN100542530C 3'- (2z)- 1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy- 1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
| 09/22/2009 | US7592477 Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases (PTPs) |
| 09/22/2009 | US7592450 used to inhibit proliferative conditions, such as cancer and psoriasis, with improved bioavailability and stability |
| 09/22/2009 | US7592445 method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis or related disorders. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount |
| 09/22/2009 | US7592372 Mixture of fudostein, acid and sweetening |
| 09/22/2009 | US7592368 HIV aspartyl protease inhibitors; solubility, bioavailability; viral and HIV infections |
| 09/22/2009 | US7592329 containing an anti-inflammatory and anti-allergic compound of the androstane series |
| 09/22/2009 | US7592323 Testosterone-repressed prostate message-2 (TRPM-2); delaying progression of prostatic tumor cells to an androgen-independent state |
| 09/22/2009 | US7592310 Induction of antibiotic proteins and peptides by LAIT/sCD14-protein |
| 09/22/2009 | US7591949 Method for the improvement of transport across adaptable semi-permeable barriers |
| 09/22/2009 | CA2454584C Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising ep4 agonist as active ingredient |
| 09/22/2009 | CA2449917C Amino acid mixture-containing agent capable of raising body temperature for food or drink use and medical use |
| 09/22/2009 | CA2397554C Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents |
| 09/22/2009 | CA2223703C Method of inhibiting viral replication in eukaryotic cells and of inducing apoptosis of virally-infected cells |
| 09/22/2009 | CA2152351C Combination of a cholesterol biosynthesis inhibitor and a .beta.-lactam cholesterol absorption inhibitor |
| 09/17/2009 | WO2009114650A1 Methods and compositions for treating inflammation and inflammation-related pathologies |
| 09/17/2009 | WO2009114597A1 Apoaequorin-containing compositions and methods of using same |
| 09/17/2009 | WO2009114516A1 Therapy for disorders of the proximal digestive tract |
| 09/17/2009 | WO2009113495A1 Liver cancer detection method using gene capable of being expressed in liver cancer-specific manner, and therapeutic and prophylactic agent for liver cancer |
| 09/17/2009 | WO2009113480A1 Therapeutic agent for cerebral infarction |
| 09/17/2009 | WO2009113436A1 Method for enhancing the anti-cancer activity of radioactive ray by using fgf33 gene inhibitor in combination with irradiation with the radioactive ray, and method for reducing adverse side effects of radioactive ray |
| 09/17/2009 | WO2009113295A1 C2orf18 as target gene for cancer therapy and diagnosis |
| 09/17/2009 | WO2009112878A1 Drug delivery to the anterior and posterior segments of the eye using eye drops. |
| 09/17/2009 | WO2009112609A1 Novel uses of sodium 4-phenylbutyrate (4 pba) and the pharmaceutically acceptable salts thereof |
| 09/17/2009 | WO2009112274A2 Novel dosage and formulation |
| 09/17/2009 | WO2009112273A2 Novel dosage and formulation |
| 09/17/2009 | WO2009112156A1 Palatable solid composition comprising antacid and saliva stimulant |
| 09/17/2009 | WO2009112033A1 Use of npy y5 receptor antagonists for the prevention of psychostimulant and opioid abuse |
| 09/17/2009 | WO2009092892A3 Novel composition for treating the side effects of anticancer treatments |
| 09/17/2009 | WO2009068190A3 Combinations comprising a prostaglandin and uses thereof |
| 09/17/2009 | US20090234000 Triptolide Analogs for the Treatment of Autoimmune and Inflammatory Disorders |
| 09/17/2009 | US20090233995 Use of drug combinations for treating insulin resistance |
| 09/17/2009 | US20090233973 Epothilone derivatives for the treatment of multiple myeloma |
| 09/17/2009 | US20090233871 Complexed polypeptide and adjuvant for improved vaccines |
| 09/17/2009 | US20090233865 Nutritional Compositions |
| 09/17/2009 | US20090233314 Functional domain and associated molecule of dock2 essentially required in lymphocyte migration |